Siemens Targets 80% Factory Automation Through Industrial AI
AI Could Transform Industrial Automation
Siemens plans to increase factory automation to 70%–80% by applying artificial intelligence (AI) across manufacturing operations. The company currently estimates that automation covers approximately 30%–40% of factory production work. Cedrik Neike, a member of the Siemens Managing Board, believes AI can help close this gap. Moreover, the strategy could strengthen manufacturing competitiveness in Germany and other high-wage economies.The initiative combines industrial automation hardware, software, digital twins, and AI models. Together, these technologies aim to improve production efficiency while helping manufacturers maintain local operations.
Industrial Automation Faces Growing Productivity Pressure
Manufacturers in high-wage countries face rising labor costs and increasing international competition. Cedrik Neike estimates that factories must improve productivity by 7%–9% annually to remain competitive. However, conventional automation alone may not deliver these gains consistently across complex production environments.Therefore, Siemens sees AI as a way to accelerate factory modernization. Manufacturers can use intelligent control systems to optimize production sequences, reduce process interruptions, and improve resource utilization. In addition, AI-assisted analysis can help engineers identify bottlenecks and evaluate potential process improvements.For industrial facilities using PLC and DCS platforms, these developments could expand the role of data-driven optimization. Nevertheless, the actual benefits will depend on production requirements, equipment compatibility, and implementation quality.Digital Twins Support AI-Driven Factory Automation
Siemens and Nvidia are developing technologies that combine digital twins with AI models. A digital twin creates a virtual representation of a physical factory, production line, or industrial process. Engineers can use this virtual environment to examine operating conditions and test proposed changes before implementation.The approach reduces the need to experiment directly on production equipment. For example, engineers can simulate workflow adjustments, evaluate equipment interactions, and identify potential production constraints. They can then assess the results before introducing validated changes to the physical facility.Siemens contributes industrial software, automation equipment, and manufacturing data. Nvidia provides computing infrastructure, simulation technologies, and AI capabilities. Their collaboration focuses on physical AI, which enables AI systems to understand and interact with real-world environments.This approach could support more flexible factory automation. However, manufacturers still need accurate models, reliable operational data, and suitable engineering validation. AI recommendations must also comply with established machine safety requirements and industrial control procedures.PLC and DCS Systems in the Physical AI Era
The expansion of AI does not eliminate the need for established industrial control systems. PLCs continue to execute machine-level control logic, while DCS platforms coordinate processes across larger industrial installations. Both remain important components of modern manufacturing infrastructure.AI can complement these systems by analyzing operational data and identifying opportunities for improvement. For instance, manufacturers may combine historical production records, equipment condition data, and simulation results to refine operating strategies.However, engineers must distinguish between optimization functions and safety-critical control functions. AI-generated recommendations should not bypass validated control logic, protective interlocks, or established safety procedures. Instead, manufacturers should integrate AI through carefully designed interfaces and appropriate engineering reviews.Consequently, the future of industrial automation will likely combine conventional control systems with AI-based decision support. This model allows manufacturers to explore new capabilities without abandoning proven control architectures.Siemens Erlangen Campus: A Manufacturing Investment Through 2030
Siemens is investing €500 million to expand its Erlangen site by 2030. The development includes a technology campus, an innovation center, and additional production capacity. The company plans to strengthen its position in power electronics while expanding its AI-driven manufacturing capabilities.The existing Erlangen facility also provides a practical environment for testing digital manufacturing technologies. Siemens reports that AI, digital twins, and robotics have contributed to a 69% productivity increase and a 42% reduction in energy consumption.These figures illustrate the potential impact of coordinated digitalization. However, manufacturers should evaluate such results against their own production conditions, baseline measurements, and investment requirements.Siemens also reports more than 100 AI applications at the site. These applications demonstrate how manufacturers can introduce AI across multiple operational areas rather than treating it as a single automation project.Power Electronics and Energy Transition Manufacturing
Power electronics play an important role in electrification, renewable energy integration, and modern power conversion systems. Siemens intends to expand its manufacturing capabilities in this area through its Erlangen investment.The initiative also connects factory automation with broader industrial energy objectives. More efficient production processes can help manufacturers manage energy consumption while increasing output. In addition, digital twins can help engineers evaluate production changes before committing resources to physical modifications.For manufacturers supplying electrical infrastructure and energy technology, these capabilities may support more responsive production planning. Nevertheless, output quality, product traceability, and process stability remain important performance requirements.Automation Targets Raise Questions About Manufacturing Jobs
Siemens' automation strategy also raises questions about employment. In March 2025, the company announced plans to cut 5,600 jobs in its factory automation business by late 2027. The announcement included approximately 2,600 positions in Germany.This context highlights a central challenge for industrial manufacturers. Automation can help retain production in high-cost economies, but it can also reduce demand for certain tasks. The overall employment impact depends on investment decisions, production growth, workforce skills, and the creation of new technical roles.Therefore, companies pursuing higher automation levels must consider workforce development alongside technology deployment. Training in industrial software, robotics, data analysis, and AI integration could help employees adapt to changing production requirements.Labor representatives will likely assess Siemens' 80% automation target through its practical effects on staffing, job quality, and long-term manufacturing investment.The Global Race for Physical AI
Siemens and Nvidia are not alone in pursuing AI technologies for physical operations. Robotics developers are also exploring AI models that help machines perform tasks in changing environments. These developments include synthetic training data, spatial sensing, and foundation models for robotic manipulation.Synthetic data can help developers generate training scenarios without collecting every example from physical equipment. Meanwhile, spatial sensors provide information about surrounding objects and environmental conditions. Foundation models can help robots interpret tasks and coordinate movements.These technologies may eventually support more adaptable industrial robots and automated production lines. However, practical deployment still requires appropriate sensing, motion control, system integration, and safety validation.For industrial automation suppliers, the wider trend creates opportunities across control hardware, industrial networking, sensors, simulation software, and intelligent robotics. Manufacturers will need to assess how these technologies fit existing PLC, DCS, and supervisory control architectures.What Siemens' 80% Automation Goal Means for Manufacturers
Siemens' target reflects a broader shift from conventional automation toward AI-assisted industrial operations. Digital twins can help engineers test changes, while AI models can support analysis and process optimization. Meanwhile, established PLC and DCS platforms will continue to manage deterministic control and essential process functions.However, a higher automation percentage does not automatically guarantee better productivity. Manufacturers must also consider capital costs, equipment integration, cybersecurity, workforce training, and measurable operational results.The most practical strategy is to introduce AI where it addresses clearly defined production problems. Companies can begin with simulation, predictive analysis, and workflow optimization before expanding into more complex applications.Ultimately, Siemens' Erlangen project offers a useful example of how industrial automation and physical AI may develop together. Its long-term impact will depend on whether manufacturers can translate these technologies into measurable productivity gains while maintaining safe operations and sustainable employment.Digital CMC Consortium Unites Novartis and Rockwell Automation to Modernize Pharmaceutical Manufacturing
Pharmaceutical Industry Advances Digital CMC and Manufacturing Efficiency
Leading pharmaceutical and technology companies have launched the Digital CMC Consortium to modernize drug development and manufacturing. The initiative aims to remove information bottlenecks through standardized digital workflows and interoperable systems.The not-for-profit consortium includes Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship’s Pioneering Medicines, Stellix, ZS Associates, and QbDVision. Together, these organizations will develop practical digital solutions for Chemistry, Manufacturing and Controls (CMC).CMC covers the processes used to develop, manufacture, test, and control pharmaceutical products. However, many companies still rely on manual documentation, disconnected software, and inconsistent data formats. These limitations can slow technology transfer and complicate coordination across global manufacturing networks.The Consortium aims to address these challenges through shared data standards, reusable digital models, and interoperable infrastructure. Consequently, pharmaceutical companies can improve information exchange and reduce repetitive documentation throughout drug development.Novartis and Industry Partners Promote Digital Standards
The Digital CMC Consortium follows a pre-competitive collaboration model. Members can address common technical challenges together without independently developing overlapping solutions.The initiative integrates existing industry guidelines and identifies areas that require additional standards. Moreover, members are developing software tools and code that help companies implement these standards in practical workflows.Achim Frauenschuh, Co-Chair of the Digital CMC Consortium and Associate Director of Science and Technology Drug Substance Development at Novartis, highlighted the value of shared digital foundations.He emphasized that collaborative investment gives members access to structured data models, standardized templates, and implementation guidance. These resources can reduce duplicated engineering effort and help companies apply digital standards more consistently.For industrial automation teams, this approach reflects a broader trend toward interoperability across control systems, manufacturing software, and enterprise applications. Standardized information structures can also support more consistent communication between production facilities and pharmaceutical technology platforms.Digital Technology Transfer Becomes a Key CMC Priority
After its first year of collaboration and proof-of-concept activities, the Consortium is preparing to expand practical industry adoption. Its initial priority focuses on technology transfer between pharmaceutical companies and contract development and manufacturing organizations (CDMOs).Technology transfer requires teams to exchange process knowledge, manufacturing instructions, analytical methods, and quality information. However, document-heavy workflows can create inconsistencies when companies move processes between development laboratories and commercial production sites.The Consortium aims to replace fragmented documentation with structured, reusable digital information. This approach could simplify information handovers, improve consistency, and support collaboration across manufacturing partners.Mike Stapleton, Chairman of the Digital CMC Consortium and Chief Business Officer at QbDVision, highlighted the opportunity to extend digital transformation beyond drug discovery and clinical trials. He identified CMC as another major area where connected digital workflows can improve pharmaceutical operations.As global supply chains become more complex, companies need systems that exchange technical information accurately. Therefore, interoperability will remain important when connecting manufacturing sites, digital platforms, and regulatory processes.Industrial Automation Supports Connected Pharmaceutical Manufacturing
Digital CMC initiatives also have implications for industrial automation and pharmaceutical production systems. Modern facilities use PLC controllers, distributed control systems (DCS), industrial networks, and manufacturing execution systems to manage production activities.These technologies generate operational data that supports process monitoring, equipment control, batch execution, and quality management. However, companies gain greater value when they connect operational data with structured product and process information.For example, standardized data models can help align manufacturing parameters, process instructions, and quality records across different production environments. In addition, consistent information structures can support data exchange between plant-level control systems and higher-level manufacturing applications.The Consortium's stated focus is digital CMC rather than the development of PLC or DCS hardware. Nevertheless, its interoperability goals align with wider industrial automation efforts to reduce isolated data environments and improve manufacturing information management.AI and Digital Twins Extend the Digital CMC Roadmap
The Consortium's longer-term roadmap includes knowledge management, automated content creation, digital twins, and artificial intelligence. These capabilities could help pharmaceutical companies reuse technical knowledge across multiple development and manufacturing stages.Digital twins can represent manufacturing processes or systems using data and computational models. When supported by suitable process information, they can help teams evaluate operating conditions and investigate process behavior.AI may also assist with technical documentation, information retrieval, and structured knowledge reuse. However, pharmaceutical organizations must evaluate these applications against data quality, validation, traceability, and applicable regulatory requirements.A connected digital CMC environment could reduce information silos between research, process development, manufacturing, and quality teams. As a result, companies may gain a clearer view of process knowledge throughout the product lifecycle.Regulatory Alignment and Interoperability Shape Future Development
The Digital CMC Consortium also plans to provide a coordinated industry perspective when engaging with health authorities. Its objective is to support standards that serve internal operations and regulatory submissions.Consistent digital information can help companies manage technical documentation across development and manufacturing activities. Moreover, common standards can reduce the need to maintain separate information structures for different partners and workflows.Successful implementation will depend on industry participation, practical technical guidance, and alignment with regulatory expectations. Companies must also ensure that digital workflows preserve data integrity and provide appropriate oversight.What the Digital CMC Consortium Means for Industrial Automation
The Consortium highlights the growing importance of digital interoperability in pharmaceutical manufacturing. Although its primary mission focuses on CMC processes, its objectives intersect with broader factory automation and manufacturing digitalization trends.PLC and DCS platforms will continue to manage equipment and process operations. Meanwhile, connected data architectures can help make production information more accessible to manufacturing, engineering, and quality teams.For pharmaceutical manufacturers, the next step involves connecting digital standards with practical operational workflows. If industry partners adopt these approaches consistently, they could improve technology transfer, reduce duplicated work, and support more connected drug development.The Consortium's progress will depend on how effectively its members translate shared standards into deployable solutions. Its work also reflects a wider industry shift toward interoperable manufacturing data, digital twins, and AI-enabled process knowledge management.
Read More
Categories:
Uncategorized



